Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Federica Tomao, GianPaolo Spinelli, Patrizia Vici, Giovanni Codacci Pisanelli, GianLuca Cascialli, Luigi Frati, PierLuigi Benedetti Panici & Silverio Tomao. (2011) Current role and safety profile of aromatase inhibitors in early breast cancer. Expert Review of Anticancer Therapy 11:8, pages 1253-1263.
Read now
Read now
R. Bell & J. Lewis. (2007) Assessing the risk of bone fracture among postmenopausal women who are receiving adjuvant hormonal therapy for breast cancer. Current Medical Research and Opinion 23:5, pages 1045-1051.
Read now
Read now
Walter Jonat, Felix Hilpert & Manfred Kaufmann. (2007) Aromatase inhibitors: a safety comparison. Expert Opinion on Drug Safety 6:2, pages 165-174.
Read now
Read now
Articles from other publishers (23)
Sara Tenti, Pierpaolo Correale, Sara Cheleschi, Antonella Fioravanti & Luigi Pirtoli. (2020) Aromatase Inhibitors—Induced Musculoskeletal Disorders: Current Knowledge on Clinical and Molecular Aspects. International Journal of Molecular Sciences 21:16, pages 5625.
Crossref
Crossref
Subhajit Makar, Abhrajyoti Ghosh, Ashok Kumar & Sushil K. Singh. (2020) Recent Studies on Aromatase and Sulfatase Involved in Breast Cancer and their Inhibitors. Current Enzyme Inhibition 16:1, pages 20-44.
Crossref
Crossref
Ozlem Soran. 2019. Breast Disease. Breast Disease
757
779
.
Ozlem Soran. 2016. Breast Disease. Breast Disease
889
921
.
Irshad Ahmad & Shagufta. (2015) Recent developments in steroidal and nonsteroidal aromatase inhibitors for the chemoprevention of estrogen-dependent breast cancer. European Journal of Medicinal Chemistry 102, pages 375-386.
Crossref
Crossref
Patricia A. Mote, Anne Gompel, Chris Howe, Heidi N. Hilton, Ivana Sestak, Jack Cuzick, Mitch Dowsett, Danielle Hugol, Patricia Forgez, Karen Byth, J. Dinny Graham & Christine L. Clarke. (2015) Progesterone receptor A predominance is a discriminator of benefit from endocrine therapy in the ATAC trial. Breast Cancer Research and Treatment 151:2, pages 309-318.
Crossref
Crossref
Rachid Tanz, Nicolas Magne, Pierre Annede, Benoite Mery, Julian Jacob, Olivier Bauduceau, Jane-Chloé Trone, Jean-Baptiste Guichard, Nicolas Meillan, Youlia Kirova, Lionel Vedrine & Cyrus Chargari. (2014) Vers une approche intégrée des toxicités cardiovasculaires liées aux traitements du cancer du sein. Bulletin du Cancer 101:7-8, pages 730-740.
Crossref
Crossref
Yumie Rhee, Kijun Song, Seho Park, Hyung Seok Park, Sung-Kil Lim & Byeong Woo Park. (2013) Efficacy of a combined alendronate and calcitriol agent (Maxmarvil^|^reg;) in Korean postmenopausal women with early breast cancer receiving aromatase inhibitor: a double-blind, randomized, placebo-controlled study. Endocrine Journal, pages 167-172.
Crossref
Crossref
Cyrus Chargari, Krassen M. Kirov, Marc A. Bollet, Nicolas Magné, Lionel Védrine, Serge Cremades, Philippe Beuzeboc, Alain Fourquet & Youlia M. Kirova. (2011) Cardiac toxicity in breast cancer patients: From a fractional point of view to a global assessment. Cancer Treatment Reviews 37:4, pages 321-330.
Crossref
Crossref
R. Eastell, J. Adams, G. Clack, A. Howell, J. Cuzick, J. Mackey, M.W. Beckmann & R.E. Coleman. (2011) Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial. Annals of Oncology 22:4, pages 857-862.
Crossref
Crossref
Christos J. Markopoulos. (2010) Minimizing early relapse and maximizing treatment outcomes in hormone-sensitive postmenopausal breast cancer: efficacy review of AI trials. Cancer and Metastasis Reviews 29:4, pages 581-594.
Crossref
Crossref
Catherine Van PoznakRosemary A. HannonJohn R. MackeyMario CamponeJustus P. ApffelstaedtGlen ClackDavid BarlowAndreas MakrisRichard Eastell. (2010) Prevention of Aromatase Inhibitor–Induced Bone Loss Using Risedronate: The SABRE Trial. Journal of Clinical Oncology 28:6, pages 967-975.
Crossref
Crossref
Rowan T. Chlebowski. (2009) Aromatase Inhibitor–Associated Arthralgias. Journal of Clinical Oncology 27:30, pages 4932-4934.
Crossref
Crossref
Yuji Kumagai, Tomoe Fujita, Machiko Ozaki, Shin-ichi Yokota, Mika Maeda, Mizue Shida, Yoshio Otani, Hidetoshi Yamaya & Hideo Tsuruta. (2009) Safety, Tolerability and Pharmacokinetics of TAS-108, a Novel Anti-Oestrogen, in Healthy Post-Menopausal Japanese Women: A Phase I Single Oral Dose Study. Basic & Clinical Pharmacology & Toxicology 104:5, pages 352-359.
Crossref
Crossref
Lee S. Schwartzberg, Patrick Cobb, Frank Senecal, David Henry, Kimary Kulig, Mark S. Walker, Arthur C. Houts & Edward J. Stepanski. (2009) Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer. The Breast 18:2, pages 78-83.
Crossref
Crossref
Daniel J. Lenihan & Francisco J. Esteva. (2008) Multidisciplinary Strategy for Managing Cardiovascular Risks When Treating Patients with Early Breast Cancer. The Oncologist 13:12, pages 1224-1234.
Crossref
Crossref
Adnan Aydiner & Faruk Tas. (2008) Meta-analysis of trials comparing anastrozole and tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer. Trials 9:1.
Crossref
Crossref
Jennifer Eng-Wong, Jennifer Orzano-Birgani, Catherine K. Chow, David Venzon, Jianhua Yao, Claudia E. Galbo, Jo Anne Zujewski & Sheila Prindiville. (2008) Effect of Raloxifene on Mammographic Density and Breast Magnetic Resonance Imaging in Premenopausal Women at Increased Risk for Breast Cancer. Cancer Epidemiology, Biomarkers & Prevention 17:7, pages 1696-1701.
Crossref
Crossref
Udayan Dutta & Kartikeya Pant. (2007) Aromatase inhibitors: past, present and future in breast cancer therapy. Medical Oncology 25:2, pages 113-124.
Crossref
Crossref
R.E. Coleman, W.W. Bolten, M. Lansdown, S. Dale, C. Jackisch, D. Merkel, N. Maass & P. Hadji. (2008) Aromatase inhibitor-induced arthralgia: Clinical experience and treatment recommendations. Cancer Treatment Reviews 34:3, pages 275-282.
Crossref
Crossref
Jack Cuzick. (2008) Aromatase inhibitors in early breast-cancer treatment: The story so far. The Breast 17, pages 2-8.
Crossref
Crossref
Jason A. Zell & Frank L. Meyskens. 2008. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology
361
395
.
Eugene V. McCloskey, Rosemary A. Hannon, Geza Lakner, William D. Fraser, Glen Clack, Anna Miyamoto, Richard D. Finkelman & Richard Eastell. (2007) Effects of third generation aromatase inhibitors on bone health and other safety parameters: Results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women. European Journal of Cancer 43:17, pages 2523-2531.
Crossref
Crossref